Semax Research Overview

Semax is a synthetic peptide consisting of a fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) sequence, joined to a proline-glycine-proline tripeptide added to improve stability. It is described in the literature as an ACTH(4-10) analogue.

The ACTH-derived portion was chosen because melanocortin fragments had been reported to influence learning and attention measures in animal research without the hormonal activity of full-length ACTH.

Semax was developed in the Soviet Union and later Russia, emerging from research on behaviorally active ACTH fragments conducted from the 1970s onward.

It has a regional medical history: Semax is registered for certain uses in Russia. Regional registration is a regulatory fact about that jurisdiction and is not equivalent to approval by the United States Food and Drug Administration, which has not approved Semax. It should also not be read as confirmation of the international evidence base.

Gene expression research is the most developed mechanistic area. Studies in rat models of focal cerebral ischemia — experimentally induced reduction of blood flow to brain tissue — have reported changes in expression of genes associated with immune and vascular responses.

Other work has examined brain-derived neurotrophic factor (BDNF) and its receptor TrkB, along with monoamine system measures. Effects on enkephalin-degrading enzyme activity have also been proposed, as with related peptides.

Melanocortin receptor involvement has been considered given the ACTH-derived sequence, but a definitive receptor mechanism for Semax has not been established.

Experimental ischemia models in rodents, with gene expression profiling.

Neurotrophic signaling research, including BDNF and TrkB measures.

Behavioral neuroscience — learning and attention paradigms in animals.

Molecular signaling and transcriptomic studies in brain tissue.

Peptide stability and metabolism research.

Mechanistic and behavioral findings come overwhelmingly from rat models and cell systems.

Clinical use in Russia is supported by studies published largely in Russian-language journals. These are generally small, and systematic reviews meeting international standards are lacking.

There is no substantial body of large, randomized, internationally reported controlled trials, and Semax has not been approved in the United States. Regional medical history should be described separately from demonstrated clinical evidence.

The literature is concentrated regionally, with limited independent international replication.

Gene expression findings describe changes in experimental models and do not by themselves establish functional outcomes.

No confirmed receptor-level mechanism.

Clinical reports are small and methodologically heterogeneous.

Semax is a synthetic ACTH(4-7)-derived peptide with an added stabilizing tripeptide, studied primarily in rodent neurological models.

Gene expression work in experimental ischemia and neurotrophic signaling measures are its main research themes.

Regional registration in Russia is a regulatory fact, not evidence of efficacy by international clinical standards, and the compound is not FDA approved.

This page is provided for scientific and educational purposes only. It summarizes published laboratory research and does not constitute medical advice, does not describe any approved therapy, and does not provide instructions for human use of any kind.

SFVLAB supplies this compound strictly as a research-use-only material for laboratory investigation.